Literature DB >> 7793742

Recent experience with cancer of the ampulla of Vater in a national hospital group.

A G el-Ghazzawy1, T P Wade, K S Virgo, F E Johnson.   

Abstract

A total of 64 resections, 24 operative bypasses and 35 nonoperative biliary intubations, were performed for ampullary carcinoma in U.S. Dept. of Veterans Affairs hospitals from 1987 to 1991. Mean survival after resection was 702 days, significantly higher (ANOVA, P < or = 0.005) than that after bypass (345 days) or intubation (385 days). Operative mortality rates were similar: resection or intubation = 14%, bypass = 12%. Operative (30-day) mortality was zero in four local resections, 10% in 51 Whipples and 44% in nine total pancreatectomies. TNM staging was available for 74 patients, and mean survival after resection exceeded 2 years in 34 patients with Stage I-II (localized) cancers, was 532 days in 10 patients with Stage III (regional nodes +) and 77 days in two patients with Stage IV (metastatic) disease. However, mean survival without resection was 498 days in 14 patients with localized cancer, 634 days in two patients with regional and 215 days in 11 patients with distant metastases. Resection clearly increased survival only for Stage I cancers (P < or = 0.02). Predicted 5-year survival rates by stage after resection were: I-II = 21%, III < 10%, IV = 0%. Complications were recorded in 29 per cent of resected patients, with sepsis the most common (21% of resections). Both sepsis and GI bleeding significantly decreased mean survival (P < or = 0.05, ANOVA), but pneumonia, pancreatic fistula, or wound problems did not. Ampullary cancer is a favorable subtype of peri-ampullary cancers, but prolonged survival is also seen without resection and may be largely limited to tumors that do not involve regional nodes.

Entities:  

Mesh:

Year:  1995        PMID: 7793742

Source DB:  PubMed          Journal:  Am Surg        ISSN: 0003-1348            Impact factor:   0.688


  6 in total

1.  Adenocarcinoma of the ampulla of Vater. A 28-year experience.

Authors:  M A Talamini; R C Moesinger; H A Pitt; T A Sohn; R H Hruban; K D Lillemoe; C J Yeo; J L Cameron
Journal:  Ann Surg       Date:  1997-05       Impact factor: 12.969

2.  Clinicopathologic analysis of ampullary neoplasms in 450 patients: implications for surgical strategy and long-term prognosis.

Authors:  Jordan M Winter; John L Cameron; Kelly Olino; Joseph M Herman; Mechteld C de Jong; Ralph H Hruban; Christopher L Wolfgang; Frederic Eckhauser; Barish H Edil; Michael A Choti; Richard D Schulick; Timothy M Pawlik
Journal:  J Gastrointest Surg       Date:  2010-02       Impact factor: 3.452

3.  Adjuvant chemoradiation versus surgery alone for adenocarcinoma of the ampulla of Vater.

Authors:  Jessica Zhou; Charles C Hsu; Jordan M Winter; Timothy M Pawlik; Daniel Laheru; Michael A Hughes; Ross Donehower; Christopher Wolfgang; Umer Akbar; Richard Schulick; John Cameron; Joseph M Herman
Journal:  Radiother Oncol       Date:  2009-06-21       Impact factor: 6.280

4.  Evaluation of adjuvant chemoradiation therapy for ampullary adenocarcinoma: the Johns Hopkins Hospital-Mayo Clinic collaborative study.

Authors:  Amol K Narang; Robert C Miller; Charles C Hsu; Sumita Bhatia; Timothy M Pawlik; Dan Laheru; Ralph H Hruban; Jessica Zhou; Jordan M Winter; Michael G Haddock; John H Donohue; Richard D Schulick; Christopher L Wolfgang; John L Cameron; Joseph M Herman
Journal:  Radiat Oncol       Date:  2011-09-28       Impact factor: 3.481

5.  Pancreaticoduodenectomy for ductal adenocarcinoma of the pancreatic head with venous resection.

Authors:  Vojko Flis; Stojan Potrc; Nina Kobilica; Arpad Ivanecz
Journal:  Radiol Oncol       Date:  2016-07-19       Impact factor: 2.991

Review 6.  Surgical ampullectomy: A comprehensive review.

Authors:  Darren L Scroggie; Vasileios K Mavroeidis
Journal:  World J Gastrointest Surg       Date:  2021-11-27
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.